E.g., 03/28/2024
E.g., 03/28/2024

Scotland chooses VITEK® 2 for all NHS Microbiology Laboratories

19 March, 2007

National Procurement, a division of NHS National Services Scotland and the Scottish Microbiology Forum have awarded bioMérieux with a major contract to supply each of the 27 NHS (National Health Service) clinical microbiology laboratories in the country with a VITEK 2 system for standardising antibiotic susceptibility testing (AST) and bacterial identification.

bioMérieux Receives Major Order from BML, Japan’s Biggest Laboratory Chain

06 March, 2007

bioMérieux, a global leader in the field of in vitro diagnostics, announces today that it has received a major order from BML, Inc. (BioMedical Laboratories), the biggest Japanese private laboratory chain. bioMérieux will supply 28 VITEK® 2 XL to BML.

bioMérieux confirms its commitment to the fight against Hospital Acquired Infections

15 February, 2007

bioMérieux, a global leader in the field of in vitro diagnostics, confirms its commitment to the fight against Hospital Acquired Infections with the launch of three new products.

bioMérieux and ExonHit Therapeutics initiate their third diagnostic program

04 January, 2007

Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.

bioMérieux launches VIDAS® Troponin I Ultra

07 December, 2006

bioMérieux, a major player in the field of in vitro diagnostics, is reinforcing its commitment to combating cardiovascular diseases by launching VIDAS Troponin I Ultra, a first-line parameter in acute coronary syndrome diagnostics.

bioMérieux will be awarded up to €54.5 million by France’s Agence de l’Innovation Industrielle to pursue molecular biology research

24 November, 2006

bioMérieux today announced that it will be awarded up to €54.5 million over the next ten years by France’s Agence de l’Innovation Industrielle to help fund the “Advanced Diagnostics and New therapeutic Approaches” (ADNA) program, led by Mérieux Alliance. Of this amount, €25.6 million will be in the form of grants and €28.9 million in the form of loans. The financing is subject to approval by the European Union, which is expected to make a decision in the second quarter of 2007.

bioMérieux Award 2006 on Excellence in Pathogen Research

14 September, 2006

bioMérieux was proud to present its ninth Award on Pathogen Research at the “Eleventh Conference on Food Microbiology”, held this year by the University of Ghent, Belgium, on September 14th and 15th.

bioMérieux confirms its commitment to the fight against the AIDS virus in Africa

01 August, 2006

A major player in in vitro diagnostics specialized in the fight against infectious diseases, bioMérieux confirms its success in the fight against the AIDS virus in Africa.

Pioneering Diagnostics